NICE TA321: for treating unresectable or metastatic BRAF V600 mutation-positive melanoma. (Decision date - November 2014).
NICE TA544: with trametinib for adjuvant treatment of resected BRAF V600 mutation positive melanoma. (Decision date - Nov 2018).
NHSE SSC2444: Clinical commissioning policy: Dabrafenib and trametinib in
the treatment of patients with BRAF-mutated anaplastic thyroid cancer. NHSE
commissioned. (Decision date - November 2022).
NICE TA898 - Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer. (Decision date - July 2023)
DO NOT PRESCRIBE (DNP):
NICE TA564: with trametinib for treating advanced metastatic BRAF V600E mutation-positive NSCLC. (Terminated appraisal). (Decision date - March 2019).
Do Not Prescribe (DNP) Drug Classifications
6: Have NICE guidance that recommends they should not be used
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
